NCT01984697View on ClinicalTrials.gov

A Phase III Study of a 2-dose Regimen of a Multivalent Human Papillomavirus (HPV) Vaccine (V503), Administered to 9 to 14 Year-olds and Compared to Young Women, 16 to 26 Years Old (V503-010)

PHASE3CompletedINTERVENTIONAL

Enrollment

1,518

Participants

Timeline

Start Date

December 12, 2013

Primary Completion Date

June 19, 2015

Study Completion Date

July 24, 2017

Conditions

Human Papillomavirus Infection

Interventions

BIOLOGICAL

V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine)

V503, a 9-valent HPV (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) administered as a 0.5-mL intramuscular injection

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01984697 - A Phase III Study of a 2-dose Regimen of a Multivalent Human Papillomavirus (HPV) Vaccine (V503), Administered to 9 to 14 Year-olds and Compared to Young Women, 16 to 26 Years Old (V503-010) | Biotech Hunter | Biotech Hunter